2Epstein M.A ldos teron e as a determinant of card iovascular and renal dys function[J].J R Soc Meal,2001,94(8):378-783.
3Hostelter TH,R osenberg ME,Ibrah mi HN,et al.A ldosterone in p rogressive renal disease[J].Sem in Nephrol,2001,21(5):573-579.
4Ritz E,Rychlik,I Locatelli F,et al.End-stage renal failure in type 2 diabetes:amedical catastrophe of worldwide dmiensions[J].Am J Kidney Dis, 1999,34(5):795-808.
5Struthers AD,MacDonald TM.Review of aldosterone and angio- tension Ⅱ inducedtarget organ damage and prevention[J].Cardiov- ascular Research.2004.61 (4):663.
9Katrine JS,Kasper R,Tina R J,et al Ben eficial impact of spirono-lactone in diabetic nephrop athy[J].Kidney Int,2005,68(6):2829-2836.
10van den Meirackef AH,Baggen RG,Pauli S,et al.Spironolactone in type 2 diabeticNephropathy:effects on proteinuria,blood pressrure and renal function.J Hypertens,006,24(11):2285-2292.
3Amann K, Tyralla K. Cardiovascular changes in chronic renal failure | pathogenesis and therapy [J]. Clin Nephrol, 2002, 58 (Suppl) :S62-72.
4Bauersachs J, Fraccarono D, Ertl G, et al. Striking increase of natriuresis by low-dose spironolactone in cogestive heart failare only in combination with ACE-inhibition: mechanistic evidence to support RALES[J]. Circulation,2000,102(19):2325-2328.
5Allison A. Eddy. Molecular basis of renal fibrosis[J] 2000,Pediatric Nephrology(3-4):290～301
